placebo + olanzapine

This is a combination of a placebo (an inert substance with no active pharmacological effect) and olanzapine, an atypical antipsychotic medication. Olanzapine acts primarily as an antagonist at dopamine D2 and serotonin 5HT2A receptors, rebalancing these neurotransmitters to improve symptoms in conditions such as schizophrenia and bipolar disorder. The combination "placebo + olanzapine" is not a marketed pharmaceutical product but may be used in clinical trials where one group receives both agents for blinding or control purposes. Olanzapine is developed for the treatment of schizophrenia, bipolar I disorder (including manic/mixed episodes), and agitation associated with these disorders[1][2][3][6]. Placebo has no therapeutic effect.